Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8667-8673

  Alvares Da Silva, Mario Reis ^a,b   De Oliveira, Claudia Pinto Marques Souza ^a   Stefano, José Tadeu ^a   Barbeiro, Hermes V ^a   Barbeiro, Denise ^a   Soriano, Francisco G ^a   Farias, Alberto Queiroz ^a   Carrilho, Flair José ^a   D'Albuquerque, Luiz Augusto Carneiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cardiovascular disease; Cell adhesion molecules; Endothelial biomarkers; Metabolic syndrome; Nonalcoholic steatohepatitis

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; AMYLOID A PROTEIN; AMYLOID PROTEIN; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; GLUCOSE BLOOD LEVEL; INSULIN; LIPID; CHOLESTEROL; GLUCOSE; SERUM AMYLOID A; SERUM AMYLOID P; TACROLIMUS;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAMINGHAM RISK SCORE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN RESISTANCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; ADVERSE EFFECTS; AGED; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; FOLLOW UP; GLUCOSE HOMEOSTASIS; HOSPITAL ADMISSION; INSULIN BLOOD LEVEL; LIVER BIOPSY; OUTPATIENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; INSULIN; LIPIDS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904393166     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8667     Document Type: Article

References (32)

1. Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int 2010; 30: 948-957 [PMID: 20500807 DOI: 10.1111/j.1478-3231.2010.02274.x]
2. Stravitz RT, Carl DE, Biskobing DM. Medical management of the liver transplant recipient. Clin Liver Dis 2011; 15: 821-843 [PMID: 22032531 DOI: 10.1016/j.cld.2011.08.007]
3. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293 [PMID: 18756451 DOI: 10.1002/lt.21524]
4. Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B, Zein NN. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl 2012; 18: 370-375 [PMID: 22140067 DOI: 10.1002/lt.22468]
5. Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, Fix OK, Kay N, Abecassis MI, Gheorghiade M, Flaherty JD. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231 [PMID: 21737011 DOI: 10.1016/j.jacc.2011.03.026]
6. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206 [PMID: 20451282 DOI: 10.1016/j.jhep.2010.01.040]
7. Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol 2010; 56: 106-108 [PMID: 20620725]
8. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138 [PMID: 17531663] (Pubitemid 46783865)
9. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40: 1215-1220 [PMID: 16477805] (Pubitemid 43117845)
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461] (Pubitemid 40770284)
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497 [PMID: 11368702]
12. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004; 24: e19-e24 [PMID: 14766740]
13. Matsudo SM, Matsudo VR, Araujo TL, Andrade DR, Andrade EL, de Oliveira LC, Braggion GF. The Agita São Paulo Program as a model for using physical activity to promote health. Rev Panam Salud Publica 2003; 14: 265-272 [PMID: 14662077] (Pubitemid 37499293)
14. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Post-transplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670 [PMID: 19938136 DOI: 10.1002/lt.21952]
15. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl 2011; 17: 23-31 [PMID: 21254341 DOI: 10.1002/lt.22140]
16. Calan M, Calan O, Gonen MS, Bilgir F, Kebapcilar L, Kulac E, Cinali T, Bilgir O. Examination of adhesion molecules, homocysteine and hs-CRP in patients with polygenic hypercholesterolemia and isolated hypertriglyceridemia. Intern Med 2011; 50: 1529-1535 [PMID: 21804277]
17. Yajnik CS, Joglekar CV, Chinchwadkar MC, Sayyad MG, Deshpande SS, Naik SS, Bhat DS, Ganpule A, Shetty P, Yudkin JS. Conventional and novel cardiovascular risk factors and markers of vascular damage in rural and urban Indian men. Int J Cardiol 2013; 165: 255-259 [PMID: 21925749 DOI: 10.1016/j.ijcard.2011.08.053]
18. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421 [PMID: 18081738]
19. Aharinejad S, Krenn K, Zuckermann A, Schäfer R, Paulus P, Seebacher G, Wolner E, Grimm M. Matrix metalloproteases and their tissue inhibitor in cardiac transplantation. Eur J Cardiothorac Surg 2007; 32: 48-51 [PMID: 17482473] (Pubitemid 46874981)
20. Migita K, Maeda Y, Abiru S, Nakamura M, Komori A, Yokoyama T, Takii Y, Mori T, Yatsuhashi H, Eguchi K, Ishibashi H. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci 2006; 78: 2510-2515 [PMID: 16303143]
21. Mueller AR, Platz KP, Haak M, Undi H, Müller C, Köttgen E, Weidemann H, Neuhaus P. The release of cytokines, adhesion molecules, and extracellular matrix parameters during and after reperfusion in human liver transplantation. Transplantation 1996; 62: 1118-1126 [PMID: 8900313] (Pubitemid 26376663)
22. Elias-Miro M, Massip-Salcedo M, Jimenez-Castro M, Peralta C. Does adiponectin benefit steatotic liver transplantation? Liver Transpl 2011; 17: 993-1004 [PMID: 21671349 DOI: 10.1002/lt.22358]
23. Rabelo F, Oliveira CP, Faintuch J, Mazo DF, Lima VM, Stefano JT, Barbeiro HV, Soriano FG, Alves VA, Carrilho FJ. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg 2010; 20: 906-912 [PMID: 20454933]
24. Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets retain high levels of active plasminogen activator inhibitor 1. PLoS One 2011; 6: e26762 [PMID: 22069469 DOI: 10.1371/journal.pone.0026762]
25. Wiest R, Weigert J, Wanninger J, Neumeier M, Bauer S, Schmidhofer S, Farkas S, Scherer MN, Schäffler A, Schölmerich J, Buechler C. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine 2011; 53: 178-183 [PMID: 20637651 DOI: 10.1016/j.cyto.2010.06.013]
26. Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 2013; 164: 221-226 [PMID: 21784542 DOI: 10.1016/j.ijcard.2011.07.016]
27. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-2811 [PMID: 21734787 DOI: 10.3748/wjg.v17.i23.2801]
28. Oliveira CP, Stefano JT, Alvares-da-Silva MR. Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review. Expert Rev Gastroenterol Hepatol 2013; 7: 361-364 [PMID: 23639094 DOI: 10.1586/egh.13.19]
29. Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, Chandhoke V, Younossi ZM. Expression of cytokine signaling genes in morbidly obese patients with nonalcoholic steatohepatitis and hepatic fibrosis. Obes Surg 2009; 19: 617-624 [PMID: 19280268 DOI: 10.1007/s11695-009-9814-x]
30. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22 [PMID: 21254340 DOI: 10.1002/lt.22198]
31. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995; 9: 463-471 [PMID: 8645890]
32. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation 2009; 87: 763-770 [PMID: 19295324 DOI: 10.1097/TP.0b013e318198d734]